Kaletra

Lopinavir, ritonavir, the active ingredient in Kaletra, is a protease inhibitor presented as a 200 mg/50 mg tablet for oral use. It is employed in the treatment of HIV‑1 infection in both adults and children, reducing viral replication when combined with other antiretroviral agents. The combination leverages ritonavir’s ability to inhibit CYP3A metabolism, thereby boosting lopinavir plasma concentrations and enhancing antiviral efficacy.

GNH USA supplies Kaletra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company emphasizes quality assurance and regulatory compliance in every shipment.

Kaletra, a protease inhibitor used in antiretroviral therapy, is indicated for the following HIV‑1 related conditions: - HIV‑1 infection in adults: reduces plasma viral load, improves CD4+ cell counts, and delays disease progression when administered together with a full antiretroviral regimen. - HIV‑1 infection in children: provides virologic suppression, supports immune system recovery, and helps maintain growth and development as part of pediatric combination therapy. - Treatment‑experienced HIV‑1 infection: offers an alternative for patients who have developed resistance to other protease inhibitors, contributing to continued viral control in salvage regimens.

Kaletra may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate, may lead to dehydration. - Nausea and vomiting: gastrointestinal discomfort that can affect oral intake. - Headache: mild to moderate intensity, usually transient. - Elevated triglycerides: increase in blood lipid levels, may require monitoring. - Abdominal pain: cramp‑like discomfort in the stomach region. - Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects: - Hepatotoxicity: liver enzyme elevations or hepatitis requiring monitoring. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Severe hypersensitivity reactions: including rash, Stevens‑Johnson syndrome, or anaphylaxis.

When prescribing Kaletra, several precautions should be observed to ensure safe and effective use. - Pregnancy: Category C; weigh potential benefits against risks and monitor fetal development. - Liver function: Assess hepatic enzymes before initiation and periodically during therapy. - Adherence: Emphasize strict dosing schedule to prevent resistance development. - Drug interactions: Avoid concomitant use of strong CYP3A inducers that may reduce efficacy. - Lipid monitoring: Check triglyceride and cholesterol levels regularly due to possible elevations. - Store at ambient temperature: keep tablets in the original container, protect from moisture and heat.

Kaletra interacts with several medicines; understanding the level of interaction guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A inducers (e.g., rifampin, St. John’s wort): markedly reduce lopinavir concentrations. - Certain antiarrhythmic agents (e.g., amiodarone): may cause dangerous cardiac effects when combined. - Concomitant use with other protease inhibitors at high doses: increases risk of toxicity.

Moderate Interactions (Monitor Closely): - Statins (simvastatin, lovastatin): increased plasma levels may lead to myopathy; dose adjustment required. - Warfarin: potential alteration of INR; monitor coagulation parameters. - Anticonvulsants (carbamazepine, phenytoin): may lower lopinavir exposure; consider alternative therapy.